Carboplatin in metastatic castration-resistant prostate cancer patients with molecular alterations of the DNA damage repair pathway: the PRO-CARBO phase II trial.

Authors:
Coquan E; Penel N; Lequesne J; Leman R; Lavaud P and 12 more

Journal:
Ther Adv Urol

Publication Year: 2024

DOI:
10.1177/17562872241229876

PMCID:
PMC10903225

PMID:
38425504

Journal Information

Journal Title: Ther Adv Urol

Detailed journal information not available.

Publication Details

Subject Category: Urology & Nephrology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"The authors declare that there is no conflict of interest."

Evidence found in paper:

"Funding: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by an inter-regional academic grant from the French Cancer Research Hospital Program (PHRCI-17-081) and by the French League Against Cancer. The trial was promoted by the Comprehensive Cancer Centre François Baclesse, Caen, France. The funding agencies were not involved in the design and conduct of the study, nor the collection, management, analysis, interpretation of data, the writing of the manuscript, and the decision to submit the manuscript for publication."

Evidence found in paper:

"Trial registration: NCT03652493, EudraCT ID number 2017-004764-35."

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025